Sector benchmark
Biotech · Series C
Indicative reference figures for a Biotech company at Series C stage. These are the same defaults this tool prefills into a Tier 1 form, shown on their own so you can sanity-check a number without running the full model.
Valuation multiples
- EV / Revenue multiple
- 8.0x
- EV / EBITDA multiple
- 20.0x
Investor return expectations
- Target investor IRR
- 35%
- Expected future dilution
- 15%
Unit economics
- Annual churn
- 3%
- CAC payback
- 30 months
- Rule of 40
- 15%
Source: Neuvosight indicative sector reference — generic industry ranges, not a live data feed. · As of: 2026-01-01
Model your own Biotech company →Want a second pair of eyes on this?
Book a 20-minute model review →